|
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mantle cell lymphoma (MCL) is an aggressive subtype of B-cell non-Hodgkin lymphomas characterized by (over)expression of BCL2.
|
31004002 |
2019 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
BCL2 was exclusively controlled by Rel-B in HL.
|
30941572 |
2019 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
B cell signaling agents, including ibrutinib, idelalisib, and the BCL-2 inhibitor venetoclax have become an integral part of therapy for patients with non-Hodgkin's lymphomas.
|
29644450 |
2018 |
|
Hodgkin Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To gain insight into the contribution of BCLW to B-cell lymphomas and its potential to confer resistance to BCL2 inhibitors, we investigated the expression of BCLW and the other antiapoptotic BCL2 family members in six different B-cell lymphomas.<b>Experimental Design:</b> We performed a large-scale gene expression analysis of datasets comprising approximately 2,300 lymphoma patient samples, including non-Hodgkin and Hodgkin lymphomas as well as indolent and aggressive lymphomas.
|
28855351 |
2017 |
|
Hodgkin Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BCL2 mutation spectrum in B-cell non-Hodgkin lymphomas and patterns associated with evolution of follicular lymphoma.
|
24496723 |
2015 |
|
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BCL2 expression has also been found previously in about 10 to 20% of BL cases, and BCL2 translocation is a major mechanism for the deregulation of BCL2 expression in non-Hodgkin lymphomas.
|
26182827 |
2015 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
'Double-Hit' (DH) B cell non-Hodgkin lymphomas are characterized by the presence of a MYC rearrangement and additional rearrangement(s) most commonly involving BCL2 and/or BCL6.
|
24761809 |
2014 |
|
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, we assume the incidence of t(14;18) in HL associated with FL is higher than previously believed and BCL2 expression derived from t(14;18) may play a role in the pathogenesis of HL associated with FL.
|
22827759 |
2012 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical investigation of SNDX-275 alone or in combination with Bcl-2 inhibitors is warranted in patients with HL.
|
21767511 |
2011 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737.
|
19557638 |
2009 |
|
Hodgkin Disease
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
BCL2 and BCL3 are recurrent translocation partners of the IGH locus.
|
18940474 |
2008 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The spectrum of B-cell non-Hodgkin lymphomas with dual IgH-BCL2 and BCL6 translocations.
|
18628087 |
2008 |
|
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Bcl-2 is an anti-apoptotic member of a family of anti- and pro-apoptotic proteins that is upregulated in a variety of cancers and specifically overexpressed through chromosomal translocation in some non-Hodgkin lymphomas.
|
18289046 |
2007 |
|
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
This study aimed to investigate the expression of the proteins bcl2, bcl-xl, mcl1, bax, bak, bad, bid, bim, and active caspase 3, and the TUNEL (terminal deoxynucleotidyl transferase-mediated in situ labeling) index to gain further insight into the apoptosis profile of classical HLs.
|
16949642 |
2007 |
|
Hodgkin Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association between telomere length and BCL2 gene rearrangements in low- and high-grade non-Hodgkin lymphomas.
|
17074584 |
2006 |
|
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Translocation t(14;18) and gain of chromosome 18/BCL2: effects on BCL2 expression and apoptosis in B-cell non-Hodgkin's lymphomas.
|
16193090 |
2005 |
|
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BCL2 is upregulated in nodal and extranodal B-cell non-Hodgkin's lymphomas, with a consequent antiapoptotic effect.
|
15377339 |
2004 |
|
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Bcl-2 functions as a key survival factor for lymphocytes and is highly expressed in a majority of non-Hodgkin's lymphomas.
|
15651174 |
2004 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The H-RS cells of 62 classic Hodgkin lymphomas were bcl-2-positive in 35 cases (56.45%), p53-positive in 14 (22.58%), and positive for both EBV latent membrane protein-1 and EBER in 37 (59.68%); there was complete concordance of results for EBV by both procedures.
|
12966346 |
2003 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed both CD95-related apoptotic signaling and its effects on the expression of several factors involved in the regulation of apoptotic mechanisms including: caspase-3, caspase-8, bcl-2, bcl-x, and Bax in HD cell lines (L-428, L-540, HDLM-2, HS-445, and KM-H2).
|
11376869 |
2001 |
|
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
bcl-2 expression in non-Hodgkin's lymphomas is not associated with bcl-2 gene rearrangements.
|
11380403 |
2001 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We describe a patient with HD who showed t(14;18) in hyperdiploid cells using fluorescence in situ hybridization (FISH) and HRS cells which were strongly positive for BCL2 by immunohistochemistry.
|
11150598 |
2000 |
|
Hodgkin Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Rearrangement of the BCL2 gene is an important parameter for the differential diagnosis of non-Hodgkin lymphomas.
|
10564590 |
2000 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
P53, p21, bcl-2, bax, Rb and Ki67 proteins were detected in Hodgkin and Reed-Sternberg (HRS) cells in 35/56, 56/56, 24/56, 23/56, 56/56 and 56/56 cases of HL, respectively.
|
10809363 |
2000 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
p53, bcl-2 and bax abnormalities in non-Hodgkin's lymphomas of the head and neck.
|
10766396 |
2000 |